



Online

# Cancer Careers Day - November 19, 2021

## Is there a life after your PhD?

Doing a Postdoc and not sure where your talents and your hard work will lead you?  
Doing your specialist training or working as a CS and considering other career options ?

## We will help you to shed light on those questions with our joint Career Day events!

Together, the MSNZ/UCCH and the UCCSH have established a series of events where we will give you an overview about career options within and outside of the „classic“ academical world. In discussions and interviews with experts from all kinds of fields from classic (but also unconventional) „university jobs“ over pharmaceutical industry to communication, law, PR and others you will get a glimpse of what all of these jobs actually look like and which skills are needed to succeed.

## On November 19, 2021 we will introduce „Career Options in the Pharmaceutical Industry“:



### Zoom Meeting

<https://uni-hamburg.zoom.us/j/64021678248?pwd=Mk91NTJqdEUxOGNQazNRS09MR2k5UT09> (Link ist klickbar)

Meeting-ID: 640 2167 8248 - Kenncode: 03685430

Please register at: [ucch.science.info@uke.de](mailto:ucch.science.info@uke.de)

## Program:

- 1:00 - 1:15 pm** Welcome and introduction „Career Days“: Prof. Susanne Sebens (UCCSH, Kiel), Dr. Inga Melzer (MSNZ, Hamburg)
- 1:15 - 1:45 pm** Dr. Stefan Langhammer (Astellas Pharma GmbH; life science consulting): „Career Options in Pharmaceutical Companies as a Bioscientist/Physician“
- 1:45 - 2:00 pm** Q&A
- 2:00 - 3:00 pm** Panel discussion with colleagues working in pharmaceutical companies: Startups vs. „global players“, trainee programs, differences to working in an academic setting, skills needed, biographies and other topics – based on YOUR questions & input  
Hosts: Dr. Inga Melzer & Prof. Susanne Sebens
- 3:00 - 3:30 pm** Breakout rooms with the panelists

## Hosts:

Prof. Susanne Sebens (UCCSH, Kiel)



Prof. Sebens studied biology in Braunschweig and did her PhD in immunology and oncology at the DKFZ in Heidelberg. After a Postdoc phase in Heidelberg and Kiel she became a Group Leader and was appointed W2 Professor and later, in 2015, W3 Professor and Director of the Institute for Experimental Cancer Research at Kiel University. She also is a board member of the UCCSH and member of the MSNZ HH advisory board.


Dr. Inga Melzer (MSNZ, Hamburg)



Dr. Melzer studied biochemistry and did her PhD at the Bernhard Nocht Institute in Hamburg. After 10 years of experience as Postdoc and Group Leader in oncology in Frankfurt/M and Mainz, she changed fields and became Scientific Coordinator at the UCT Mainz. In 2019, she returned to Hamburg to become Executive Director and Coordinator at the MSNZ HH. She has one daughter.

## Panelists

**Sebastian Kreiter, TRON and BioNTech SE, Mainz**



Dr. Kreiter studied medicine in Mainz. In the academic group of Ugur Sahin and Özlem Türeci he started off the preclinical development for in vitro transcribed mRNA cancer vaccination, achieving fundamental scientific and technical proof of concept. Currently he is Director of the “Immune Therapy Development Center” at TRON - Translational Oncology at the Johannes Gutenberg University in Mainz and acts a Senior Vice President “Immunotherapy & Preclinical Research” at BioNTech.

**Jürgen Kupper, 2cureX GmbH, Hamburg**



Prof. Dr. Kupper obtained his PhD at Brandeis University, Waltham, MA, USA. After a post-doctoral period at the Ecole Normale Supérieure in Paris and at the Max Planck Institute for Biochemistry in Martinsried he held different positions in the healthcare industry. Currently, he serves as Managing Director and Chief Product Officer at 2cureX GmbH. In addition, he is Professor at the MSH Medical School Hamburg. He is father of two daughters.

**Tina Zimmermann, Boehringer Ingelheim, Biberach a.d. Riß**



Dr. Zimmermann studied biochemistry in Berlin. After her PhD thesis at the Johannes Gutenberg University in Mainz, she initially continued her work in the neurosciences as a Postdoctoral Scientist at AbbVie in Ludwigshafen before becoming Lab Head/PI with a focus on cardiometabolic diseases at Boehringer Ingelheim, Biberach a.d. Riß.

**Tobias Hain, Recordati Rare Diseases, Ulm**



Dr. Hain studied biology in Cologne, Düsseldorf and Mainz, where he also did his PhD thesis in immunology. After a brief intermediate time as a Postdoc, he became Trainee at Biotest AG, Dreieich. Since 2017 he held several positions in both global and smaller pharmaceutical companies. Currently, he is a Medical Science Liaison Manager at Recordati Rare Diseases in Ulm. He is a father of four.

**Philine Ahrdorf, Eli Lilly and Company, Bad Homburg**



Dr. Ahrdorf is a Medical Doctor by training and is board certified for internal medicine and emergency medicine. She worked as Resident and Consultant at the University Hospital in Tübingen and in an office-based setting, before she became Medical Affairs Manager at Astra Zeneca in 2016. Very recently (November 2021) she became the Medical Portfolio Lead at Eli Lilly and Company in Bad Homburg. Dr. Ahrdorf has two kids.

**Stefan Langhammer, Astellas Pharma GmbH, Munich**



Dr. Langhammer studied molecular biology in Berlin. After his PhD in virology he became Project Leader and Consultant at Bayer Schering Pharma AG in Berlin. Since 2006, he held different positions in- and outside academia at the Robert Koch Institute, Novartis, Pfizer, Astra Zeneca and AbbVie including Medical Science Liaison, Project Leader, Study Site Manager and others. He is currently working as Therapeutic Area Lead Oncology at Astellas Pharma GmbH.